clemastine has been researched along with MS (Multiple Sclerosis) in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, JR; Cordano, C; Cruz-Herranz, A; Green, AJ; Guglielmetti, C; Lorrain, D; Sin, JH; Stebbins, K; Timmons, G; Xin, W; Yiu, HH | 1 |
| El-Maraghy, SA; Kamel, AS; Kortam, MA; Motawi, TK; Said, SE | 1 |
| Huang, JK; Kouki, T; Ohno, N; Osanai, Y; Yamazaki, R | 1 |
| Koushki, A; Moghaddasi, M; Mohebi, N; Nabovvati, M; Rabani, S; Sardarinia, M; Soltansanjari, M | 1 |
| Aimoto, M; Hagiwara-Nagasawa, M; Kawakami, S; Nagasawa, Y; Omura, K; Takahara, A | 1 |
| Cohen, JA; Tesar, PJ | 1 |
| Abounasr, A; Arnow, S; Bevan, C; Boscardin, WJ; Chan, JR; Cree, BA; Devereux, M; Friessen, M; Gelfand, JM; Gerona, R; Green, AJ; Hauser, SL; Henry, RG; Inman, J; Mei, F; Nobuta, H; von Büdingen, HC; Zhu, A | 1 |
| Amato, MP; Trojano, M | 1 |
| Chan, JR; Etxeberria, A; Fancy, SPJ; Franklin, RJM; Green, A; Hauser, SL; Lee, S; Mayoral, SR; Mei, F; Miao, E; Niu, J; Presley, B; Redmond, SA; Shen, YA; Xiao, L; Zhao, C | 1 |
2 trial(s) available for clemastine and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Randomized control trial of evaluation of Clemastine effects on visual evoked potential, nerve fiber layer and ganglion cell layer complex in patients with optic neuritis.
Topics: Adult; Clemastine; Double-Blind Method; Evoked Potentials, Visual; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Sclerosis; Nerve Fibers; Optic Neuritis; Prospective Studies; Retinal Ganglion Cells; Tomography, Optical Coherence; Treatment Outcome; Vision Disorders; Young Adult | 2020 |
Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.
Topics: Adult; Clemastine; Cross-Over Studies; Double-Blind Method; Evoked Potentials, Visual; Female; Humans; Male; Multiple Sclerosis; Remyelination; Tomography, Optical Coherence; Treatment Outcome | 2017 |
7 other study(ies) available for clemastine and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Validating visual evoked potentials as a preclinical, quantitative biomarker for remyelination efficacy.
Topics: Animals; Biomarkers; Clemastine; Evoked Potentials, Visual; Humans; Multiple Sclerosis; Myelin Sheath; Remyelination | 2022 |
Modulation of p38 MAPK and Nrf2/HO-1/NLRP3 inflammasome signaling and pyroptosis outline the anti-neuroinflammatory and remyelinating characters of Clemastine in EAE rat model.
Topics: Animals; Clemastine; Encephalomyelitis, Autoimmune, Experimental; Heme Oxygenase-1; Inflammasomes; Multiple Sclerosis; Neuroinflammatory Diseases; NF-E2-Related Factor 2; NLR Family, Pyrin Domain-Containing 3 Protein; NLR Proteins; p38 Mitogen-Activated Protein Kinases; Pyroptosis; Rats | 2023 |
Pharmacological treatment promoting remyelination enhances motor function after internal capsule demyelination in mice.
Topics: Animals; Clemastine; Cuprizone; Demyelinating Diseases; Disease Models, Animal; Internal Capsule; Lysophosphatidylcholines; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin Sheath; Oligodendroglia; Remyelination | 2023 |
Torsadogenic potential of a novel remyelinating drug clemastine for multiple sclerosis assessed in the rabbit proarrhythmia model.
Topics: Action Potentials; Animals; Atrioventricular Block; Bradycardia; Clemastine; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Heart Ventricles; Infusions, Intravenous; Long QT Syndrome; Multiple Sclerosis; Rabbits; Torsades de Pointes | 2020 |
Clemastine fumarate for promotion of optic nerve remyelination.
Topics: Clemastine; Cross-Over Studies; Double-Blind Method; Humans; Multiple Sclerosis; Optic Nerve; Pyrrolidines; Remyelination | 2017 |
Multiple sclerosis in 2017: Progress in multiple sclerosis - from diagnosis to therapy.
Topics: Antibodies, Monoclonal, Humanized; B-Cell Activating Factor; Clemastine; Humans; Immunologic Factors; Multiple Sclerosis | 2018 |
Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis.
Topics: Animals; Cell Differentiation; Cells, Cultured; Clemastine; Drug Evaluation, Preclinical; Female; High-Throughput Screening Assays; Histamine H1 Antagonists; Mice; Mice, Inbred C57BL; Mice, Transgenic; Multiple Sclerosis; Muscarinic Antagonists; Nanostructures; Nerve Fibers, Myelinated; Oligodendroglia; Rats; Rats, Sprague-Dawley; Regeneration | 2014 |